Andrew K. Balo - 06 Jul 2021 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
Officer
Signature
By: Jereme Sylvain For: Andrew K Balo
Issuer symbol
DXCM
Transactions as of
06 Jul 2021
Net transactions value
-$1,279,228
Form type
4
Filing time
08 Jul 2021, 19:45:51 UTC
Previous filing
07 Jun 2021
Next filing
04 Aug 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Sale $247,676 -578 -3.5% $428.51 15,805 06 Jul 2021 by Trust F1, F2, F3
transaction DXCM Common Stock Sale $171,732 -400 -2.5% $429.33 15,405 06 Jul 2021 by Trust F1, F3, F4
transaction DXCM Common Stock Sale $736,253 -1,710 -11% $430.56 13,695 06 Jul 2021 by Trust F1, F3, F5
transaction DXCM Common Stock Sale $123,566 -286 -2.1% $432.05 13,409 06 Jul 2021 by Trust F1, F3, F6
holding DXCM Common Stock 16,533 06 Jul 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2 This transaction was executed in multiple trades at prices ranging from $428.125 to $429.060. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F3 Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.
F4 This transaction was executed in multiple trades at prices ranging from $429.141 to $429.401. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.
F5 This transaction was executed in multiple trades at prices ranging from $430.270 to $430.919. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.
F6 This transaction was executed in multiple trades at prices ranging from $431.455 to $432.050. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.

Remarks:

*EVP Regulatory Strategy Clinical Affairs and Strategic Partnership Development